Navigation Links
Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
Date:5/6/2010

QUEBEC CITY, May 6 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. ( AEZS, TSX: AEZ), ("the Company") a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation for AEZS-108, its doxorubicin targeted conjugate compound, for the treatment of ovarian cancer. AEZS-108 is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.

Juergen Engel, Ph. D., President and CEO of Aeterna Zentaris stated, "We are very pleased with AEZS-108 gaining orphan-drug designation for ovarian cancer from the FDA as it would provide it with extra market exclusivity protection. We look forward to reporting the final results from our ongoing European Phase 2 study in ovarian and endometrial cancer, later this year."

About Orphan-Drug Designation

Orphan-drug designation is granted by the FDA Office of Orphan Products Development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. The designation provides the drug developer with a seven-year period of U.S. marketing exclusivity if the drug is the first of its type approved for the specified indication or if it demonstrates superior safety, efficacy, or a major contribution to patient care versus another drug of its type previously granted the designation for the same indication. It also provides tax credits for clinical research costs, the ability to apply for annual grant funding, clinical research trial design assistance and waiver of Prescription Drug User Fee Act (PDUFA) filing fees.

About Ovarian Cancer

Ovaria
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2014)... University of Pennsylvania researchers has now applied a ... other nanoscopic structures. By passing nanoscale spheres and ... the team was able to measure the electrical ... suggest new ways of using this technique, known ... smallest scale. , The research was led ...
(Date:9/26/2014)... Research and Markets  has announced the ... Markets: Market Developments, Growth Areas and Opportunities" report ... comprehensive global end-user study and market analysis relating to ... in the laboratory. Market findings from this ... by research scientists and clinicians who routinely use nucleic ...
(Date:9/26/2014)... Molecular Biology deals with the ... regulation of cellular activity and its behaviour. It emphasise ... with its environment within the genome. Knowledge on molecular ... therapeutic methodologies for the diagnosis, prognosis and the treatment ... Dr. Srinubabu Gedela, MD of OMICS Publishing Group ...
(Date:9/26/2014)... (PRWEB) September 26, 2014 Talon ... and Assemblies for the Semiconductor, Medical Device, ... it has won the Minnesota Business magazine’s Employee ... companies for excellence in helping Minnesota-based employees improve ... in our people, our processes and our capabilities ...
Breaking Biology Technology:Penn team studies nanocrystals by passing them through tiny pores 2Penn team studies nanocrystals by passing them through tiny pores 3Penn team studies nanocrystals by passing them through tiny pores 4DNA and RNA Sample Preparation Markets: Market Developments, Growth Areas and Opportunities 2DNA and RNA Sample Preparation Markets: Market Developments, Growth Areas and Opportunities 3Understanding Genetics and Molecular Biology to Avert Dreadful Medical Challenges during Open Access Week 2Understanding Genetics and Molecular Biology to Avert Dreadful Medical Challenges during Open Access Week 3Talon Innovations Wins Minnesota Business Magazine Award 2Talon Innovations Wins Minnesota Business Magazine Award 3
... Educational program offers unique resources to empower transplant patients ... ... Oct. 17 Astellas Pharma US,Inc. (Pink Sheets: ALPMF), a ... Society (ITNS), a leading transplant,professional organization, announced a collaborative partnership ...
... to Dominate the Type 2 Diabetes Market, According to a ... New Report from Decision Resources, ... have released a new report finding that Merck,will obtain blockbuster antidiabetic ... uptake of their DPP-IV inhibitor, Januvia.,Januvia will see rapid uptake as ...
... 24, at 1:30 p.m. EDT, ALAMEDA, Calif., ... a biopharmaceutical company developing innovative therapies,for the treatment ... to discuss third quarter results on Wednesday, October ... Kenneth Chahine, Chief Executive,Officer, and Michael Coffee, Chief ...
Cached Biology Technology:Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 2Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 3Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011 2Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011 3Avigen, Inc. Announces Third Quarter 2007 Earnings Conference Call 2
(Date:9/29/2014)... annual Advocacy Awards will ... advancing medical progress to improve the health and ... take place on Wednesday, March 11, 2015, at ... , The 2015 Advocacy Award winners are ABC,s ... founder of the Milken Institute and FasterCures; Dr. ...
(Date:9/29/2014)... beginning of the age of dinosaurs, gigantic reptilesdistant relatives ... and others in water and it was thought they ... University of Tennessee, Knoxville, researcher in the thigh of ... , Stephanie Drumheller, an earth and planetary sciences ... Sterling Nesbitt examined 220-million-year-old bite marks in the thigh ...
(Date:9/29/2014)... Institute (DOE JGI), a DOE Office of Science ... have been selected for the 2015 Community Science ... waters, and from plant root micro-ecosystems, to the ... the CSP 2015 projects portfolio highlights diverse environments ... , "These projects catalyze JGI,s strategic shift in ...
Breaking Biology News(10 mins):Research!America to honor leaders in medical and health research advocacy 2Research!America to honor leaders in medical and health research advocacy 3Research!America to honor leaders in medical and health research advocacy 4Tooth serves as evidence of 220 million-year-old attack 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 32015 DOE JGI's science portfolio delves deeper into the Earth's data mine 42015 DOE JGI's science portfolio delves deeper into the Earth's data mine 52015 DOE JGI's science portfolio delves deeper into the Earth's data mine 62015 DOE JGI's science portfolio delves deeper into the Earth's data mine 72015 DOE JGI's science portfolio delves deeper into the Earth's data mine 82015 DOE JGI's science portfolio delves deeper into the Earth's data mine 9
... neighbors, and now researchers reporting in the June 22 issue ... they have a motive. It appears that chimps, and especially ... gain territory. "The take-home is clear and simple," ... each other. They kill their neighbors. Up until now, we ...
... which aims to develop a new, higher-yielding rice plant which could ... by an academic at the University of Sheffield. Currently, more ... a day and nearly one billion live in hunger. Over the ... about 50 per cent and water scarcity will grow. About half ...
... international public-private consortium to build the most detailed map ... of three pilot projects and the deposition of the ... use by the research community. In addition, work has ... database containing information from the genomes of 2,500 people ...
Cached Biology News:Why chimpanzees attack and kill each other 2Rice yields researched to tackle food security issues 2Rice yields researched to tackle food security issues 3Freely available data supporting next generation of human genetic research 2Freely available data supporting next generation of human genetic research 3Freely available data supporting next generation of human genetic research 4Freely available data supporting next generation of human genetic research 5Freely available data supporting next generation of human genetic research 6